Comparative preclinical toxicology and pharmacology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vitro and in rodents and primates
| Autor: | L R, Morgan, A H, Rodgers, D, Fan, K, Soike, M, Ratterree, B W, Sartin, T J, Harrison |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Lung Neoplasms Carcinogenicity Tests Eye Infections Administration Oral Antineoplastic Agents Bone Marrow Cells Breast Neoplasms Mice Inbred Strains Skin Diseases Rats Sprague-Dawley Mice Phenols Chlorocebus aethiops Tumor Cells Cultured Animals Humans Melanoma Dose-Response Relationship Drug Reproduction Hydrazones Fibroblasts Kidney Neoplasms Rats Colonic Neoplasms Female Rabbits Injections Intraperitoneal |
| Zdroj: | In vivo (Athens, Greece). 11(1) |
| ISSN: | 0258-851X |
| Popis: | 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) is being evaluated for its anticancer activities. Acute, subacute and chronic oral, dermal, opthalmic and dermal LD50 and acceptance studies in adult mice, rats, rabbits and monkeys demonstrated some vomiting at 5 g/kg doses in monkeys but otherwise no unacceptable toxicities. In vitro, T.I. for A-007 were calculated using murine bone marrow GM-CFC and human cancer cell lines. A relative oral bioavailability factor of 2% was calculated for rats and monkeys for plasma A-007. Non-compartmental pharmacokinetic analysis suggests enterohepatic circulation. Plasma A-007 could not be detected after applying a 0.25% gel topically. Generally, A-007 is well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|